首页|基于FAERS数据库的索拉非尼不良事件信号挖掘与分析

基于FAERS数据库的索拉非尼不良事件信号挖掘与分析

扫码查看
目的 挖掘与分析索拉非尼不良事件(ADE)险信号,为临床安全用药提供参考。方法 检索美国FDA不良反应报告系统(FAERS)数据库,收集2005年第4季度至2023年第3季度共72个季度不良反应报告信息,采用报告比值比(ROR)法和比例报告比值(PRR)法对索拉非尼所致的不良事件报告进行数据挖掘与分析。结果 共收集到索拉非尼ADE报告18148份,共检测到有效ADE信号689个,涉及26个系统器官分类,主要集中在胃肠系统疾病、全身性疾病及给药部位各种反应、皮肤及皮下组织疾病。ADE发生频次前3位分别是腹泻(n=2741)、手足皮肤反应(n=2097)和皮疹(n=1587)。ADE发生强度前3位分别是异常凝血酶原升高(ROR=326。03)、甲胎蛋白升高(ROR=189。82)和手足皮肤反应(ROR=75。10)。ADE在索拉非尼用药30天内发生最多。结论 应用索拉非尼治疗时应做好患者用药评估,治疗期间密切关注患者胃肠道和皮肤反应,保证患者安全用药。
Data Mining and Analysis of ADE Signal for Sorafenib Based on the Data-base of FAERS
OBJECTIVE To mine and analyze the adverse drug reaction(ADE)signal for soradenib,and to provide reference for clinical safe drug use.METHODS A total of 72 quarterly adverse reaction reports from the fourth quarter of 2005 to the third quarter of 2023 were collected from the FDA adverse events reporting system(FAERS)database.The ADE reports caused by sorafenib were mined and analyzed using the reporting odds ratio(ROR)method and proportional reporting ratio(PRR)method.RESULTS A total of 18148 ADE reports of sor-afenib were collected,and a total of 689 effective ADE signals were detected,involving 26 systematic and organ clas-sifications,mainly focusing on gastrointestinal disorders,general disorders and administration site conditions,skin and subcutaneous tissue disorders.The top 3 ADE frequency were diarrhea(n=2741),hand-foot skin reaction(n=2097)and rash(n=1587).The top 3 ADE intensity were abnormal prothrombin elevation(ROR=326.03),alpha-fetoprotein elevation(ROR=189.82)and hand-foot skin reaction(ROR=75.10).The majority of ADEs occurred within 30 days of sorafenib administration.CONCLUSION Patient medication should be evaluated when sorafenib is used.During treatment,patients'gastrointestinal and skin reactions should be closely monitored to ensure safe med-ication.

SorafenibAdverse eventSignal miningReporting odds ratio methodProportional reporting ratio method

马曾庆、李素素、赵欣、赵建国、吴连平、林玉

展开 >

南京市高淳人民医院,江苏南京 211300

索拉非尼 不良事件 信号挖掘 报告比值比法 比例报告比值法

2024

海峡药学
中国药学会福建分会

海峡药学

影响因子:0.643
ISSN:1006-3765
年,卷(期):2024.36(10)